Veru Inc.

Contributing Author

Recent Articles by Veru Inc.

Aug-12	Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress VERU GlobeNewswire
Aug-11	Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study VERU GlobeNewswire
Aug-06	Veru Announces Reverse Stock Split VERU GlobeNewswire
Aug-05	Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th VERU GlobeNewswire
Jul-22	Veru to Participate in the 2025 BTIG Virtual Biotech Conference VERU GlobeNewswire
Jun-24	Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation VERU GlobeNewswire
Jun-11	Veru to Participate in the Virtual BTIG Obesity Health Forum VERU GlobeNewswire
May-28	Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone VERU GlobeNewswire
May-08	Veru Participates in a Virtual Investor KOL Connect Segment VERU GlobeNewswire
May-08	Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress VERU GlobeNewswire
May-01	Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 VERU GlobeNewswire